NO962526D0 - Fremgangsmåte for forebyggelse eller behandling av en sykdom karakterisert ved neoplasmatiske celler som uttrykker CD 40 - Google Patents

Fremgangsmåte for forebyggelse eller behandling av en sykdom karakterisert ved neoplasmatiske celler som uttrykker CD 40

Info

Publication number
NO962526D0
NO962526D0 NO962526A NO962526A NO962526D0 NO 962526 D0 NO962526 D0 NO 962526D0 NO 962526 A NO962526 A NO 962526A NO 962526 A NO962526 A NO 962526A NO 962526 D0 NO962526 D0 NO 962526D0
Authority
NO
Norway
Prior art keywords
disease characterized
treating
preventing
cells expressing
express
Prior art date
Application number
NO962526A
Other languages
English (en)
Other versions
NO320354B1 (no
NO962526L (no
Inventor
Richard J Armitage
William C Fanslow
Dan L Longo
William J Murphy
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22628670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO962526(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO962526D0 publication Critical patent/NO962526D0/no
Publication of NO962526L publication Critical patent/NO962526L/no
Publication of NO320354B1 publication Critical patent/NO320354B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19962526A 1993-12-23 1996-06-14 Anvendelse av et CD40-bindende protein som har evne til a binde CD40 og hindrer binding av CD40 til CD40-L ved fremstilling av et middel for forebyggelse eller behandling av en neoplasmatisk sykdom. NO320354B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17266493A 1993-12-23 1993-12-23
PCT/US1994/014767 WO1995017202A1 (en) 1993-12-23 1994-12-21 Method of preventing or treating disease characterized by neoplastic cells expressing cd40

Publications (3)

Publication Number Publication Date
NO962526D0 true NO962526D0 (no) 1996-06-14
NO962526L NO962526L (no) 1996-08-23
NO320354B1 NO320354B1 (no) 2005-11-28

Family

ID=22628670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19962526A NO320354B1 (no) 1993-12-23 1996-06-14 Anvendelse av et CD40-bindende protein som har evne til a binde CD40 og hindrer binding av CD40 til CD40-L ved fremstilling av et middel for forebyggelse eller behandling av en neoplasmatisk sykdom.

Country Status (13)

Country Link
US (1) US5674492A (no)
EP (1) EP0751781B1 (no)
JP (1) JPH09507074A (no)
AT (1) ATE267607T1 (no)
AU (1) AU680102B2 (no)
CA (1) CA2179196A1 (no)
DE (1) DE69433820T2 (no)
DK (1) DK0751781T3 (no)
ES (1) ES2222463T3 (no)
NO (1) NO320354B1 (no)
NZ (1) NZ278740A (no)
PT (1) PT751781E (no)
WO (1) WO1995017202A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997022256A1 (en) * 1995-12-19 1997-06-26 National Jewish Center For Immunology And Respiratory Medicine Method to regulate cd40 signaling
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
CZ244399A3 (cs) * 1997-01-10 1999-10-13 Biogen, Inc. Použití sloučeniny anti-CD40L pro výrobu léku pro léčení imunologických onemocnění
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
IL136731A0 (en) * 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
WO1999036783A1 (en) * 1998-01-14 1999-07-22 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis of melanoma
US7338767B1 (en) 1998-01-14 2008-03-04 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis, prognosis and/or treatment of melanoma
US5965712A (en) * 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
ATE310806T1 (de) * 1998-09-29 2005-12-15 Uab Research Foundation Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen
CA2357035A1 (en) * 1998-12-29 2000-07-06 University Of Vermont And State Agricultural College Use of cd40 engagement to alter t cell receptor usage
AU5178800A (en) * 1999-06-01 2000-12-18 Cornell Research Foundation Inc. Activation of dendritic cells to enhance immunity
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001016180A2 (en) 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US7172759B2 (en) 2000-02-01 2007-02-06 Pangenetics Bv Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies
AU4761601A (en) 2000-04-11 2001-10-23 Genentech Inc Multivalent antibodies and uses therefor
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001255740B2 (en) * 2000-04-25 2006-03-16 Immunex Corporation Method for treatment of tumors using photodynamic therapy
BR0110364A (pt) * 2000-04-25 2003-12-30 Idec Pharma Corp Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central
JP4202127B2 (ja) * 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
WO2002060485A2 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
ATE507839T1 (de) * 2001-04-02 2011-05-15 Genentech Inc Kombinationstherapie
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP1684869B1 (en) 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for b cell-related cancers
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544852A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
CN1938045B (zh) 2003-11-04 2014-03-26 诺华疫苗和诊断公司 治疗自身免疫和炎性疾病以及器官移植排异的拮抗性抗-cd40抗体的应用
EP2243491A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CA2608750A1 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
KR100991010B1 (ko) 2005-05-26 2010-10-29 제넨테크, 인크. 인간화 항-ｃｄ４０ 항체 및 그의 사용 방법
AU2006308606C1 (en) 2005-11-01 2013-07-25 Novartis Ag Uses of anti-CD40 antibodies
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
JP5730576B2 (ja) 2007-11-07 2015-06-10 ジェネンテック， インコーポレイテッド 抗ｃｄ４０抗体による治療に対するｂ細胞リンパ腫の応答性を評価するための方法及び組成物
BRPI1011394A8 (pt) 2009-04-18 2018-06-26 Genentech Inc método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
RS57087B1 (sr) 2011-04-21 2018-06-29 Bristol Myers Squibb Co Polipeptidi antitela koji antagonizuju cd40
BR112013027829B1 (pt) 2011-04-29 2022-05-10 Apexigen, Inc Anticorpos anti-cd40 ou fragmentos de ligação aos antígenos destes, composição que compreende os ditos anticorpos e uso da dita composição para tratar ou melhorar os sintomas de câncer, doença autoimune ou doença inflamatória
DK2914627T3 (da) 2012-10-30 2021-07-12 Apexigen Inc Anti-cd40-antistoffer og fremgangsmåder til anvendelse
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
CR20170592A (es) 2015-05-29 2018-02-13 Abbvie Inc Anticuerpos anti-cd40 y sus usos
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
WO2017188215A1 (ja) * 2016-04-27 2017-11-02 国立大学法人大阪大学 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0897983T3 (da) * 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment

Also Published As

Publication number Publication date
WO1995017202A1 (en) 1995-06-29
EP0751781A1 (en) 1997-01-08
AU680102B2 (en) 1997-07-17
NZ278740A (en) 1998-05-27
ATE267607T1 (de) 2004-06-15
AU1516895A (en) 1995-07-10
NO320354B1 (no) 2005-11-28
EP0751781A4 (en) 1999-09-22
EP0751781B1 (en) 2004-05-26
DE69433820T2 (de) 2005-06-23
NO962526L (no) 1996-08-23
PT751781E (pt) 2004-09-30
DE69433820D1 (de) 2004-07-01
DK0751781T3 (da) 2004-08-09
ES2222463T3 (es) 2005-02-01
US5674492A (en) 1997-10-07
JPH09507074A (ja) 1997-07-15
CA2179196A1 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
NO962526L (no) Fremgangsmåte for forebyggelse eller behandling av en sykdom karakterisert ved neoplasmatiske celler som uttrykker CD 40
Paronetto et al. Chronic liver injury induced by immunologic reactions. Cirrhosis following immunization with heterologous sera.
Fleischmajer The pathophysiology of scleroderma.
BR9306226A (pt) Composiçao de cura de feridas e tratamento de distúrbios fibróticos e método para a sua preparaçao
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
NO993847L (no) FremgangsmÕter og preparater for behandling av allergisk astma og andre sykdommer ved anvendelse av deskarboetoksyloratadin
MY113490A (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
NO954612D0 (no) Metoder og preparater for å behandle ooforektomiserte kvinner
CA2278616A1 (en) Adenoviruses having altered hexon proteins
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
Linardaki, KA Boki, A Fertakis, AG Tzioufas Pure Red Cell Aplasia as Presentation of Systemic Lupus Erythematosus: Antibodies to Erythropoietin: CASE REPORT
Bartholomew et al. Investigation of relationships between collagens, elastin and proteoglycans in bovine thoracic aorta by immunofluorescence techniques
EP0482089A4 (en) Methods of treating or preventing autoimmune uveoretinitis in mammals
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
AU6299596A (en) Prevention of a disease having the characteristics of diabetes
Meier-Ruge et al. Effect of yttrium 90 on experimental allergic arthritis in rabbits.
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
WO1989000166A3 (en) Growth hormone related peptide
SE9300139D0 (sv) Manufacture of a new drug
EP0791360A3 (en) Treatment of septic shock with anti-TNF antibodies
EP0300675A3 (en) Method for the improvement of cyclosporine therapy
NO890932L (no) Modifiserte proteiner.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
NZ329403A (en) Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L
Scornik et al. The significance of protein degradation in the regulation of liver growth

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees